Evaxion A/S’s (EVAX) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Evaxion A/S (NASDAQ:EVAX) in a research note issued to investors on Monday morning,Benzinga reports. The brokerage currently has a $16.00 target price on the stock.

A number of other brokerages have also commented on EVAX. Wall Street Zen upgraded Evaxion A/S to a “hold” rating in a research note on Friday, June 27th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Evaxion A/S in a report on Tuesday, October 14th. Two equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, Evaxion A/S presently has a consensus rating of “Hold” and an average price target of $13.50.

Evaxion A/S Stock Down 16.7%

EVAX opened at $5.44 on Monday. Evaxion A/S has a 1-year low of $1.20 and a 1-year high of $15.50. The company has a current ratio of 3.42, a quick ratio of 3.42 and a debt-to-equity ratio of 1.73. The stock has a market capitalization of $7.63 million, a price-to-earnings ratio of -4.12 and a beta of 0.23. The business has a 50 day moving average of $4.23 and a 200-day moving average of $2.89.

Evaxion A/S (NASDAQ:EVAX) last posted its quarterly earnings data on Thursday, August 14th. The company reported ($0.76) earnings per share for the quarter, missing the consensus estimate of ($0.50) by ($0.26). The firm had revenue of $0.04 million during the quarter. As a group, sell-side analysts anticipate that Evaxion A/S will post -0.15 earnings per share for the current year.

Institutional Investors Weigh In On Evaxion A/S

A hedge fund recently bought a new stake in Evaxion A/S stock. XTX Topco Ltd purchased a new position in shares of Evaxion A/S – Sponsored ADR (NASDAQ:EVAX) during the 1st quarter, according to the company in its most recent disclosure with the SEC. The fund purchased 16,281 shares of the company’s stock, valued at approximately $30,000. XTX Topco Ltd owned about 1.16% of Evaxion A/S as of its most recent SEC filing. Institutional investors own 11.04% of the company’s stock.

About Evaxion A/S

Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of metastatic melanoma; EVX-02, a DNA-based vaccine that is in Phase 1/2a trial designed to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, DNA-based cancer vaccine for the treatment of various cancers.